Globeflex Capital L P Acquires New Shares in Bioventus Inc. $BVS

Globeflex Capital L P acquired a new position in Bioventus Inc. (NASDAQ:BVS) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 165,865 shares of the company’s stock, valued at approximately $1,566,000.

A number of other hedge funds have also bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after acquiring an additional 1,538 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Bioventus by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after purchasing an additional 26,103 shares during the last quarter. Legal & General Group Plc boosted its holdings in Bioventus by 100.9% in the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock worth $473,000 after purchasing an additional 35,873 shares during the last quarter. Rhumbline Advisers grew its position in Bioventus by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after purchasing an additional 11,133 shares during the period. Finally, Marshall Wace LLP grew its position in Bioventus by 32.5% in the 2nd quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after purchasing an additional 51,951 shares during the period. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Down 2.5%

Shares of BVS stock opened at $14.02 on Tuesday. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. Bioventus Inc. has a 12 month low of $6.26 and a 12 month high of $15.89. The stock has a market cap of $1.18 billion, a P/E ratio of 18.21, a P/E/G ratio of 1.83 and a beta of 0.63. The company has a 50 day simple moving average of $12.01 and a two-hundred day simple moving average of $10.18.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The business had revenue of $153.21 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts expect that Bioventus Inc. will post 0.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BVS. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, August 17th. Canaccord Genuity Group lifted their price objective on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Barrington Research set a $18.00 price objective on Bioventus in a research report on Thursday, August 6th. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 6th. Finally, Craig Hallum reissued a “buy” rating and issued a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.80.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.